Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Leo Rasche

Showing results (21-30 of 170) with videos related to

Pageof 17
Sort By:
European Journal of Haematology|March 12, 2014
Primary bone marrow diffuse large B-cell lymphoma affecting distal parts of the legs as a cause of persisting B symptomsConstantin Lapa, Markus Knott, Leo Rasche, et al.
Frontiers in Immunology|January 11, 2021
Toxicities of Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma: An Overview of Experience From Clinical Trials, Pathophysiology, and Management StrategiesXiang Zhou, Leo Rasche, K Martin Kortüm, et al.
Cancer Treatment Reviews|April 22, 2017
Immunologic approaches for the treatment of multiple myelomaLeo Rasche, Niels Weinhold, Gareth J Morgan, et al.
Leukemia|May 20, 2021
The mutagenic impact of melphalan in multiple myelomaFrancesco Maura, Niels Weinhold, Benjamin Diamond, et al.
Future Oncology (London, England)|March 12, 2021
Management of patients with difficult-to-treat multiple myelomaJoshua Richter, Karthik Ramasamy, Leo Rasche, et al.
Leukemia & Lymphoma|July 19, 2019
Response to daratumumab in rituximab-resistant EBV-associated PTLD following allogenic stem cell transplantation from an EBV seronegative donorPatrick-Pascal Strunz, Marc Schmalzing, Anke Heidemeier, et al.
Annals of Hematology|February 15, 2014
The lymphoma-like polychemotherapy regimen "Dexa-BEAM" in advanced and extramedullary multiple myelomaLeo Rasche, Susanne Strifler, Johannes Duell, et al.
Blood Cancer Discovery|September 25, 2024
T Cell-Redirecting Bispecific Antibodies in Multiple Myeloma: Optimal Dosing Schedule and Duration of TreatmentNiels W C J van de Donk, Leo Rasche, Surbhi Sidana, et al.
Haematologica|December 2, 2017
Expression of programmed death-1 on lymphocytes in myeloma patients is lowered during lenalidomide maintenanceSophia Danhof, Martin Schreder, Stefan Knop, et al.
Annals of Hematology|July 20, 2020
COVID-19 infection in patients with multiple myeloma: a German-Chinese experience from Würzburg and WuhanXiang Zhou, Tao Bai, Katharina Meckel, et al.
Pageof 17

Showing results (21-30 of 170) with videos related to

Sort By:
Pageof 17
European Journal of Haematology|March 12, 2014
Primary bone marrow diffuse large B-cell lymphoma affecting distal parts of the legs as a cause of persisting B symptomsConstantin Lapa, Markus Knott, Leo Rasche, et al.
Frontiers in Immunology|January 11, 2021
Toxicities of Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma: An Overview of Experience From Clinical Trials, Pathophysiology, and Management StrategiesXiang Zhou, Leo Rasche, K Martin Kortüm, et al.
Cancer Treatment Reviews|April 22, 2017
Immunologic approaches for the treatment of multiple myelomaLeo Rasche, Niels Weinhold, Gareth J Morgan, et al.
Leukemia|May 20, 2021
The mutagenic impact of melphalan in multiple myelomaFrancesco Maura, Niels Weinhold, Benjamin Diamond, et al.
Future Oncology (London, England)|March 12, 2021
Management of patients with difficult-to-treat multiple myelomaJoshua Richter, Karthik Ramasamy, Leo Rasche, et al.
Leukemia & Lymphoma|July 19, 2019
Response to daratumumab in rituximab-resistant EBV-associated PTLD following allogenic stem cell transplantation from an EBV seronegative donorPatrick-Pascal Strunz, Marc Schmalzing, Anke Heidemeier, et al.
Annals of Hematology|February 15, 2014
The lymphoma-like polychemotherapy regimen "Dexa-BEAM" in advanced and extramedullary multiple myelomaLeo Rasche, Susanne Strifler, Johannes Duell, et al.
Blood Cancer Discovery|September 25, 2024
T Cell-Redirecting Bispecific Antibodies in Multiple Myeloma: Optimal Dosing Schedule and Duration of TreatmentNiels W C J van de Donk, Leo Rasche, Surbhi Sidana, et al.
Haematologica|December 2, 2017
Expression of programmed death-1 on lymphocytes in myeloma patients is lowered during lenalidomide maintenanceSophia Danhof, Martin Schreder, Stefan Knop, et al.
Annals of Hematology|July 20, 2020
COVID-19 infection in patients with multiple myeloma: a German-Chinese experience from Würzburg and WuhanXiang Zhou, Tao Bai, Katharina Meckel, et al.
Pageof 17